Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company (BDX) Q2 2025 Earnings Call Transcript
Becton, Dickinson and Company (NYSE:BDX ) Q2 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer and Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer and President Chris DelOrefice - Executive Vice President and Chief Financial Officer Mike Garrison - President of the Medical Mike Feld - President of the Life Sciences Rick Byrd - President of the Interventional Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Matt Taylor - Jefferies Travis Steed - Bank of America Patrick Wood - Morgan Stanley David Roman - Goldman Sachs Matt Miksic - Barclays Operator Hello, and welcome to BD's Second Fiscal Quarter 2025 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 839-2385 for domestic calls and area code +1-402-220-7203 for international calls.
Becton Dickinson (BDX) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cramer's Stop Trading: Becton Dickinson
CNBC's Jim Cramer explains why he is keeping an eye on shares of Becton Dickinson.
Becton Dickinson (BDX) Q2 Earnings Top Estimates
Becton Dickinson (BDX) came out with quarterly earnings of $3.35 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3.17 per share a year ago.
Medical device maker Becton Dickinson cuts 2025 profit forecast on potential tariff hit
Medical device maker Becton Dickinson lowered its annual profit forecast on Thursday, in anticipation of a potential hit from U.S. President Donald Trump's tariffs, sending its shares down 5% in premarket trading.
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
Gear Up for Becton Dickinson (BDX) Q2 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Becton, Dickinson and Company: It's Wait And See For Me
Becton, Dickinson and Company is a leading medical device firm specializing in medical supplies, devices, laboratory equipment, and diagnostic products. BDX operates in three segments: BD Medical, BD Life Sciences, and BD Interventional, with plans to spin off its Biosciences and Diagnostic Solutions business in 2026. BDX has struggled over the past decade, with a 10-year CAGR of only 5.1%.
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
DGI For The DIY: 2024 Dividend Portfolio Review
This portfolio focuses on generating a growing stream of dividend income by investing in companies that consistently increase dividends. I reinvest dividends into more shares of the companies I already own to compound growth. The investment strategy is guided by specific principles to ensure consistent and disciplined investing.
BD Seeks Potential Buyers for Life Sciences Business Division
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.
